Participating Companies

AgomAb Therapeutics
The company's agonistic monoclonal antibody molecules offer a comprehensive preclinical package that simulates molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases, enabling patients to benefit from medical products and improve their livelihood. [more information]

AM-Pharma B.V.
Results from Ph 2 in 300+ pts demonstrated improvement of 40%+ OS in recAP group. Initiated Ph 3 in Q4 2020; TL safety & futility analysis on first 400 pts exp YE2021. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023. [more information]

Amniotics
In the summer of 2019, Amniotics started building its GMP facility, and in June 2020 Amniotics will submit for manufacturing authorization of its cell therapeutics to the Swedish MPA. After approval Amniotics intends to initiate clinical trials, with its most advance product PulmiCell™ which is a product based on MSCs from TAF selected for their lung relevance. [more information]

Amolyt Pharma
Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. [more information]

Amplyx Pharmaceuticals
Developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune compromised patients. This makes them susceptible to a new disease—invasive fungal infections. By treating their underlying condition, patients are now open to a new life-threatening disease. [more information]

Anima Biotech
We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. [more information]

Arvelle Therapeutics
Arvelle is headquartered in Switzerland and received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company, with investments from a global syndicate including NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. [more information]

BerGenBio
[BGBIO:OS]
NKr3,076 MM MCap
Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. [more information]

Camurus AB
[CAMX:ST]
SKr11,009 MM MCap
Developing/commercializing innovative/long-acting medicines for severe & chronic conditions (e.g. opioid dependence, pain, cancer & endocrine disorders). FluidCrystal® drug delivery technologies for improved Q of life, treatment outcomes and resource utilization. [more information]

Cantargia AB
[CANTA:ST]
SKr6,022 MM MCap
The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. Cantargia's other project, CAN10, is in the preclinical phase and is aiming to develop an IL1RAP binding antibody blocking IL-1, IL-33 and IL-36 - optimised for the treatment of systemic sclerosis and myocarditis. [more information]

Crescendo Biologics
Crescendo Biologics is a clinical stage company developing T cell enhancing therapeutics.
Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific. CB307’s unique format delivers tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. It is designed to cause the proliferation of tumour-specific T cells, creating a safe, broad, longer-lasting anti-tumour response and will be in the clinic in early 2021. [more information]

Deutsche Bank AG
[DB]
US$21,326 MM MCap
Deutsche Bank’s ADR team is part of the Trust & Agency Services business within the newly created Corporate Bank Division. Deutsche Bank was appointed as DR Bank for the largest Life Sciences sector ADR IPO of 2019 with the $582m Nasdaq listing of Genmab A/S, confirming our position as the leading issuer of capital in the US ADR markets. [more information]

Dynacure
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. [more information]

Glycostem Therapeutics
Glycostem Therapeutics is a Dutch biotech company. Glycostem Therapeutics is the trade name of the legal entity IPD Therapeutics BV, which has been established in December 2007.
Glycostem Therapeutics has developed the world's first GMP compliant NK-cell platform that is ready for industrial scale-up. [more information]

Goodwin Procter LLP
More than 1,000 corporate and litigation attorneys leverage their specific experience and assemble full-service teams to advise clients in these and adjacent industries. [more information]

Heidelberg Pharma AG
[HPHA:DB]
€179 MM MCap
Heidelberg Pharma AG (HPHA, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumor resistance mechanisms. [more information]

Horama
The company's lead candidate is HORA-PDE6B, which is in Phase I/II clinical trials with an indication in PDE6B retinitis pigmentosa. The second product will enter in the clinic in H1 2019 The company raised EUR 22.5 million of Series B venture funding from Kurma Partners, Pontifax Venture Capital, Fund+ on November 8, 2017. [more information]

ISA Pharmaceuticals BV
is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. [more information]

Kiadis Pharma N.V.
[KDS-AMS]
NK-cell platform administered as adjunct I-O on top of HSCT. Launched FIH POC trial in r/r AML patients (Feb 2020); set to launch additional HSCT trial later in 2020 w/interim data exp 2021. Presenting new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients at EBMT in 2020. Established POC in 37 patients total. [more information]

Maxcyte
[MXCT:LN]
global cell therapy company providing proprietary non-viral cell engineering technology for the next generation of cell-based therapies including gene editing and immuno-oncology. MaxCyte may be seen as a play on the cell therapy market with its blue chip client base. [more information]

Nasdaq
[NDAQ]
US$23,151 MM MCap
leading global provider of trading, clearing, exchange technology, listing, information and public company services [more information]

NorthSea Therapeutics
First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments. [more information]

Oculis Pharma
The company's novel eye-drop treatments are based on its proprietary solubilizing nanoparticle (SNP) technology that improves both the ability to formulate drugs as eye drops and their bioavailability in the eye tissues including both the front and the back of the eye, enabling hospitals to provide clients with technological advancement in ocular drug delivery. [more information]

PharmaMar SA
[PHM:ES]
Revenue generating with marine-derived and novel MoA oncology products. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Signed licensing agreement with Jazz Pharma for lurbinectedin in the US - upfront payment of $200M, $100mm on approval and up to $550M sales milestones. [more information]

Philogen
Developer of biopharmaceuticals for the treatment of angiogenesis-related disorders. The company is engaged in the discovery and development of novel biopharmaceutical products and offers antibody derivatives for the treatment of certain cancers cancer, rheumatoid arthritis and age-related macular degeneration. [more information]

PricewaterhouseCoopers
PwC is a global network of firms delivering assurance, tax and consulting services for your business. [more information]

Ryvu Therapeutics
[RVU:WAR]
Potential first in class CDK8 inhibitor for leukemias, lymphomas, and solid tumors in Ph1b in AML and high-risk MDS, PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered w Menarini). Data in 2020. Early stage pipeline addressing emerging solid tumor targets. [more information]

Sequana Medical
[SEQUA:BR]
€162 MM MCap
Sequana Medical is a commercial stage medical device company developing the alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. [more information]

Solebury Trout
With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. [more information]

Targovax
[TRVX]
Preliminary Ph1b data of OV ONCOS-102+chemo in mesothelioma results: combo mPFS=8.4 mos. vs. control mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Upcoming milestones: updated clinical & immune data in Ph2 mesothelioma (1H20); preclinical data on next-gen OV w/ double transgenes (1H20); and clinical data from Ph1 melanoma study, part 2 with extended dosing (2H20). [more information]